SCHEMBL2304994

SCHEMBL2304994

CC(C)(C)N1C[C@H](C(=O)O)[C@H](c2ccc(Cl)cc2)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ FNTA P49354 1/20 0.43
▸ PGGT1B P53609 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MC4R P32245 1/20 0.41
▸ MC5R P33032 1/20 0.41
▸ MC3R P41968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327225 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2304570 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL1267426 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL2306660 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL15252919 1.00 MEN1 (0.46) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL27393208 0.88 ALDH1A1 (0.43) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7027450 0.86 HRH3 (0.54) MEN1KMT2AMC4RMC5RMC3R
SCHEMBL29327209 0.85 RORC (0.42) KMT2AALDH1A1MC4R
SCHEMBL21029282 0.85 RORC (0.42) KMT2AALDH1A1MC4R
SCHEMBL5729817 0.85 MC4R (0.44) ALDH1A1MC4RMC5RMC3R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350060-B1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD (KR) 2013-09-18 — — EP disclosed
US-8288386-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2012-10-16 — — US disclosed
US-8236955-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2012-08-07 — — US disclosed
US-8183243-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2012-05-22 — — US disclosed
US-8039622-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2011-10-18 — — US disclosed
US-20110245500-A1 MELANOCORTIN RECEPTOR AGONISTS LG CHEM, LTD. (KR) 2011-10-06 — — US disclosed
US-20110237795-A1 MELANOCORTIN RECEPTOR AGONISTS LG CHEM, LTD. (KR) 2011-09-29 — — US disclosed
US-20110224219-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2011-09-15 — — US disclosed
EP-2350060-A2 MELANOCORTIN RECEPTOR AGONISTS LG Life Sciences Ltd (KR) 2011-08-03 — — EP disclosed
WO-2010056022-A2 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2010-05-20 — — WO disclosed
US-20100120783-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCE LTD. (KR) 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237795-A1 MELANOCORTIN RECEPTOR AGONISTS MC1R, MC3R, MC5R MEN1 899/4885KMT2A 1634/4885CYP1A2 2269/4885
US-20110245500-A1 MELANOCORTIN RECEPTOR AGONISTS MC1R, MC3R, MC5R MEN1 899/4885KMT2A 1634/4885CYP1A2 2269/4885
US-20100120783-A1 MELANOCORTIN RECEPTOR AGONISTS MC1R, MC3R, MC5R MEN1 899/4885KMT2A 1634/4885CYP1A2 2269/4885
US-20110224219-A1 MELANOCORTIN RECEPTOR AGONISTS MC1R, MC3R, MC5R MEN1 899/4885KMT2A 1634/4885CYP1A2 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback